Lymphedema Diagnostics Market Size, Share, Analysis, Trends, Growth Report, 2030

Lymphedema Diagnostics Industry Prospective:

The global lymphedema diagnostics market size was evaluated at $12 billion in 2022 and is slated to hit $19 billion by the end of 2030 with a CAGR of nearly 5.2% between 2023 and 2030.

Request Free Sample

Lymphedema Diagnostics Market: Overview

Lymphedema is a medical condition that is caused by lymphatic system damage, trauma, or congenital defects. When the damage develops greatly and the lymphatic fluid goes beyond the lymphatic transportation capacity, swelling results in the tissues of the affected area as an unusual amount of protein-rich fluid. There are two lymphedema types, primary and secondary. At birth (congenital) or at the beginning of puberty (praecox) or in adulthood (tarda), primary lymphedema may occur. Secondary lymphedema may be caused by surgery or radiation therapy and is a common result of cancer treatments that eliminate or harm lymph nodes or vessels.

Key Insights

• As per the analysis shared by our research analyst, the global lymphedema diagnostics market is projected to expand annually at the annual growth rate of around 5.2% over the forecast timespan (2023-2030)
• In terms of revenue, the global lymphedema diagnostics market size was evaluated at nearly $12 billion in 2022 and is expected to reach $19 billion by 2030.
• The global lymphedema diagnostics market is anticipated to grow rapidly over the forecast timeline owing to a rise in the occurrence of cancer and lymphedema along with technological innovations in diagnostic imaging modalities.
• In terms of technology, the lymphoscintigraphy segment is slated to register the highest CAGR over the analysis period.
• Based on disease type, the cancer segment is expected to dominate the segmental growth over the assessment timeline.
• Based on end-user, the hospitals segment is slated to register rapid growth in the upcoming years.
• Region-wise, the North American lymphedema diagnostics industry is projected to register the fastest CAGR during the assessment timeline.

Request Free Sample

Lymphedema Diagnostics Market: Growth Factors

Growing incidences of cancer and lymphedema to boost the global market trends

Rise in the occurrence of cancer and lymphedema along with technological innovations in diagnostic imaging modalities will scale up the expansion of the global lymphedema diagnostics market. Rise in the allocation of funds by private-public organizations in research activities related to lymphedema will proliferate the growth of the global market. Surging focus on improving healthcare quality will further accentuate the expansion of the market space globally. An increase in chronic disorders will expand the scope of growth of the global market in the years ahead. Rise in the number of product approvals will prompt the global market size in the coming decade. For instance, in the first quarter of 2020, AIROS Medical, Inc., a key medical device manufacturer based in the U.S., received approval from the U.S. FDA for its AIROS 8 sequential compression treatment equipment.

Lymphedema Diagnostics Market: Restraints

High prices of diagnostic imaging systems to restrict the global industry expansion by 2030

Huge costs of diagnostic imaging tools along with restricted helium supply and shorter life of radiopharmaceuticals can downsize the expansion of the lymphedema diagnostics industry across the globe. Additionally, a rise in the demand for renovated diagnostic imaging technologies can further impact the earnings of the global industry.

Lymphedema Diagnostics Market: Opportunities

Surging acceptance of lymphedema diagnostics devices to create new growth avenues for the global market over forecast timeline

Growing demand for lymphedema diagnostics equipment in developing countries will open new growth opportunities for the lymphedema diagnostics market across the globe.

Lymphedema Diagnostics Market: Challenges

Unfavorable reimbursement policies of government can prove to be detrimental to growth of the global industry over 2023-2030

Lack of favorable compensation policies can prove to be a huge challenge for the global lymphedema diagnostics industry in the years ahead. Need for high technical expertise for operating the lymphedema diagnostics equipment can further obstruct the growth of the industry in the upcoming years.

Lymphedema Diagnostics Market: Segmentation

The global lymphedema diagnostics market is sectored into technology, disease type, end-user, and region.                

In technology terms, the global lymphedema diagnostics market is segregated into lymphoscintigraphy, near IR fluorescence imaging, MRI, and ultrasound segments. Furthermore, the lymphoscintigraphy segment, which garnered nearly two-fifths of the global market revenue in 2022, is set to register the fastest CAGR in the ensuing years. The growth of the segment during the assessment timeline can be due to the non-invasive nature and reproducibility of lymphoscintigraphy technology.

Based on the disease type, the global lymphedema diagnostics industry is sectored into cancer, cardiovascular disease, inflammatory diseases, and filariasis segments. Moreover, the cancer segment, which accumulated a major chunk of the global industry share in 2022, is set to dominate the global industry over the projected timeline. The segmental surge over the estimated timeline can be a result of a rise in the occurrence of cancer of lymphedema kind along with surging awareness about diagnosing the disease.

Based on the end-user, the lymphedema diagnostics market across the globe is divided into hospitals and diagnostic centers segments. Moreover, the hospitals segment is anticipated to dominate the global market in the years ahead. The segmental elevation over the forecast period can be due to an increment in the lymphedema diagnostic methods performed in hospitals.   

Lymphedema Diagnostics Market: Report Scope

Lymphedema Diagnostics Market: Regional Insights

Asia-Pacific is predicted to maintain its dominant position in the global lymphedema diagnostics market over the analysis period

Asia-Pacific, which contributed about 60% of the global lymphedema diagnostics market revenue in 2022, will be a dominating region over the projected timeframe. In addition to this, the regional market expansion can be subject to a surge in the cases of chronic ailments along with the rise in the consciousness of real-time lymphedema diagnosis among the populace of the region. In addition to this, a rise in the research activities pertaining to development of lymphedema diagnostic procedures will steer the expansion of the market in the region.

North American lymphedema diagnostics industry is set to register the fastest CAGR in the upcoming years owing to the easy availability of strong healthcare systems in countries such as the U.S. Additionally, the presence of key players in the sub-continent will steer the regional industry surge in the years ahead.

Lymphedema Diagnostics Market: Competitive Space

The global lymphedema diagnostics market profiles key players such as:

• Bausch Health Companies
• Anacor Pharmaceuticals Inc.
• Pfizer Inc.
• Topica Pharmaceuticals Inc.
• Moberg Pharma AB
• Dr. Reddy’s Laboratories Ltd
• NovaBiotics Inc.
• GlaxoSmithKline
• Sanofi S.A.
• Merz Pharma
• Medimetriks Pharmaceuticals Inc.
• Novartis AG
• Cipla Ltd
• Allergen Inc.
• Johnson & Johnson
• Celtic Pharma
• Bayer AG
• Galderma S.A.

The global lymphedema diagnostics market is segmented as follows:

By Technology

• Lymphoscintigraphy
• Near IR Fluorescence Imaging
• MRI
• Ultrasound

By Disease Type

• Cancer
• Cardiovascular Disease
• Inflammatory Diseases
• Filariasis

By End-User

• Hospitals
• Diagnostic Centers

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa